Monitor for first U.S. commercial revenue disclosures in upcoming quarterly filings and any updates on RHTP-related contracts. The appointment of a seasoned CCO signals execution focus, but revenue traction remains unproven.
Price Chart
Executive Summary
Pulsenmore appointed med-tech veteran David Woods as Chief Commercial Officer and expanded its U.S. commercial team, following FDA De Novo authorization of its home prenatal ultrasound system. The company is exploring opportunities tied to the federal Rural Health Transformation Program, but the filing contains no financial data or revenue guidance — it is a routine executive hire and commercial expansion announcement.
Key Facts
- David Woods appointed CCO, previously CCO at Creo Medical and President/CEO of PENTAX Medical Americas.
- Pulsenmore has FDA De Novo authorization for its home prenatal ultrasound system.
- Company has launched U.S. commercial operations and entered a strategic collaboration with Ouma Health.
- Company is exploring opportunities under the U.S. federal Rural Health Transformation Program (RHTP).
- No financial figures, revenue, or guidance were disclosed in the filing.
Financial Impact
No financial figures disclosed — impact is limited to organizational strengthening.
Risk Factors
- No disclosed revenue or commercial traction — U.S. market adoption is unproven.
- Company has a lack of operating history and depends on capital markets for funding.
- Forward-looking statements about RHTP opportunities are exploratory and non-binding.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-046729 |
| Document: form6-k.htm | 0001493152-26-046729 |
| Document: 0001493152-26-046729-index-headers.html | 0001493152-26-046729 |
| Document: 0001493152-26-046729-index.html | 0001493152-26-046729 |
| Document: 0001493152-26-046729.txt | 0001493152-26-046729 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.90 | awaiting T+20 | — | $1.73 (−8.95%) |
Oct 8, 2026 18d ago | SC 13G | $1.85 | awaiting T+20 | — | $1.73 (−6.49%) |
Sep 17, 2026 5w ago | 6-K | $2.42 $1.81 | ▼ −25.21% | ▼ −26.41% | $1.73 (−28.51%) |
Sep 8, 2026 6w ago | 6-K | $2.46 $2.16 | ▼ −12.20% | ▼ −13.91% | $1.73 (−29.67%) |
Sep 2, 2026 7w ago | EFFECT | $2.55 $2.22 | ▲ +12.94% | ▲ +12.86% | $1.73 (+32.16%) |
Aug 31, 2026 8w ago | 6-K | $2.62 $2.19 | ▼ −16.41% | ▼ −16.22% | $1.73 (−33.97%) |
Aug 19, 2026 9w ago | 6-K | $3.01 $2.42 | ▼ −19.60% | ▼ −18.76% | $1.73 (−42.52%) |
Aug 17, 2026 10w ago | 6-K | $2.89 $2.41 | ▼ −16.61% | ▼ −14.63% | $1.73 (−40.14%) |
Jul 13, 2026 15w ago | 6-K | $3.62 $3.26 | ▼ −9.94% | ▼ −13.13% | $1.73 (−52.21%) |
Jul 13, 2026 15w ago | EFFECT | $3.62 $3.26 | ▼ −9.94% | ▼ −13.13% | $1.73 (−52.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers